Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Topotecan - GlaxoSmithKline

Drug Profile

Topotecan - GlaxoSmithKline

Alternative Names: Hycamtin; NK-211; Nogitecan; NSC 609699; SKF 104864; Topotecan hydrochloride

Latest Information Update: 14 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Merck Pharmaceuticals UK; Nippon Kayaku; Novartis; SCRI Development Innovations
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cervical cancer; Ovarian cancer; Small cell lung cancer
  • Discontinued Brain metastases

Most Recent Events

  • 23 Jun 2022 Novartis plans a phase I/II trial for Solid tumours (Combination therapy, Second-line therapy or greater) in August 2022 (NCT05429502)
  • 24 Aug 2021 Novartis Pharmaceuticals terminates a phase Ib/II study in Small-cell lung cancer and Ovarian cancer (Second-line therapy or greater, Combination therapy) in USA (PO)(NCT02649673)
  • 10 Jul 2019 Discontinued - Phase-III for Brain metastases (Metastatic disease) in Hungary, Poland, Russia, Canada, Slovakia, USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top